Stocky turns companies like Cabaletta Bio, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. Cabaletta Bio is a clinical-stage immunotherapy company with moderate leadership alignment (55/100) but substantial execution risk concentrated in six ongoing trials and FDA regulatory approvals. The Vulnerability Index of 75 reflects dependence on successful IND submissions and trial completions—any significant setback in the RESET, DesCAARTes, or MusCAARTes programs could materially impact valuation.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Cabaletta Bio, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 40/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Cabaletta Bio, Inc. (CABA) at 40/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Cabaletta Bio is a clinical-stage immunotherapy company with moderate leadership alignment (55/100) but substantial execution risk concentrated in six ongoing trials and FDA regulatory approvals. The Vulnerability Index of 75 refl
CABA's current Stocky Verdict is 40/100, placing it in the "Cautious" band. This composite combines a 24/100 Compounder score, 55/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Cabaletta Bio, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Cabaletta Bio, Inc. scores 55/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Cabaletta Bio, Inc.'s Vulnerability Profile scores 75/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Cabaletta Bio, Inc..
Sign up free and unlock the full analysis on CABA — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for CABA in the app.
